On March 21, 2024, the signing ceremony for the pilot proje₹ct between the Innovation Alliance (SMIA) and the "AI Diagnosis and  Treatment Committee for Rare Diseases" (hereafter referred to as the AI Committee)β took place at the Peninsula Beijing Hotel. Geng Yili, the rotating president of SMIA, and Pa∞ul Li, the chairman of the AI Committee, signed a memorandum of cooper£ation on the "Pilot Project for AI Diagnosis and Prevention of Rare >Diseases." Both parties conducted in-depth discussions on the content of the c♣ooperation and future developments, reaching a con₩sensus.

Mr.Paul Li has extensive experience in the multinational pharmaceutical industry, having held poδsitions at Eli Lilly, Abbott, Merck, Cephalon, Zhuojian Medic>al, Jack Berlin, and other multinational companies. He possesses unique ins✘ights into the diagnosis, treatment, and prevention of rare diseases and has the ability t≥o integrate global resources to promote industry innovation. Under his leadership, the AI Com©mittee will utilize advanced scientific and technological innov≠ations such as big data, cloud computing, the Internet of Things, art★ificial intelligence, and mobile internet, as well as shared innovation models.‌ This will drive public welfare innovation in AI diagnosis, treaσtment, medication, and payment for rare diseases, providing compliant and operational solutions ≈for all parties in the medical and pharmaceutical ecosystems of the  Greater Bay Area, Yangtze River Delta, and Beijing-Tianjin-Hebei regions. The AI Committeeλ will also formulate corresponding service norms and quality standards.

The pilot project of the AI Committee aims to form a value-closed loop within the "go↑vernment-hospital-doctor-insurance/patient-commercial-manufacturer-pharmacy-third-party service γunits" ecosystem, achieving service sharing, business symbiosis,£ and innovation for the benefit of all ecosystem p&articipants. This will offer rare disease patients in China a new experience of "AI Diagnosis and   Prevention + Public Welfare Sharing Model," enhance hospital informatization, intelligγence, precision, and convenience, increase resource sharing, reduce the need for patients to viαsit hospitals frequently, and improve public satisfaction and a sense of ≤achievement.

The core mission of the AI Committee's pilot project is to be patient-centered, usi↑ng AI for diagnosis and prevention as a link, and based on information technolo"gy, intelligence, and standardized public welfare ×services, to create an "all-ecosystem sharing platform for rare disease diagnosis and tγreatment," achieving collaboration among medical institutions, ™ pharmaceuticals, and social sectors.